FDA approves Colcrys for gout treatment
PHILADELPHIA The Food and Drug Administration has approved an additional use of a drug used to treat gout.
URL Pharma announced the FDA approval of Colcrys (colchicine) for the prevention of gout flares. The drug was approved in July to treat gout flares once they began to appear.
“With the FDA’s approval of Colcrys for the prevention of gout flares, patients and physicians will now be able to realize the full therapeutic potential of Colcrys as a cornerstone therapy in the management of gout,” URL Pharma CEO Richard Roberts said in a statement. “Our clinical research on colchicine — the first of its kind ever conducted — has brought colchicine manufacturing, dosing, safety and efficacy information into compliance with current FDA standards.”